Literature DB >> 10833088

How come I've got it? (A review of Helicobacter pylori transmission).

M Deltenre1, E de Koster.   

Abstract

Numerous epidemiological studies have shown the two main risk factors for Helicobacter pylori acquisition: childhood and low socio-economic level both in developing and developed countries. Nevertheless, in the absence of ubiquitous extra-human reservoir(s), the route(s) for person-to-person transmission remains undetermined. Very recent data favour the oro-oral route: besides gastric mucosa, mouth might be a sanctuary site and the oro-oral transmission hypothesis seems applicable worldwide. Nevertheless, the gastro-oral route (vomiting, gastro-oesophageal reflux) is still possible and deserves further research. In developing countries, feco-oral transmission (perhaps through the water supply) might be a significant mechanism of human contamination both for primary infection in children and perhaps, reinfection in adults.

Entities:  

Mesh:

Year:  2000        PMID: 10833088     DOI: 10.1097/00042737-200012050-00001

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  3 in total

Review 1.  Helicobacter pylori interactions with host serum and extracellular matrix proteins: potential role in the infectious process.

Authors:  J Daniel Dubreuil; Giuseppe Del Giudice; Rino Rappuoli
Journal:  Microbiol Mol Biol Rev       Date:  2002-12       Impact factor: 11.056

2.  Development of two PCR-based techniques for detecting helical and coccoid forms of Helicobacter pylori.

Authors:  M Shahamat; M Alavi; J E M Watts; J M Gonzalez; K R Sowers; D W Maeder; F T Robb
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

3.  Magnitude of Helicobacter pylori and associated risk factors among symptomatic patients attending at Jasmin internal medicine and pediatrics specialized private clinic in Addis Ababa city, Ethiopia.

Authors:  Gemechu Shiferaw; Dessie Abera
Journal:  BMC Infect Dis       Date:  2019-02-06       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.